Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 17/20 | 0.45 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19667501 | 0.89 | PTGDR2 (0.46) | PTGDR2P2RX3ESR2 | |
| SCHEMBL19679340 | 0.88 | PTGDR2 (0.46) | PTGDR2P2RX3ESR2 | |
| SCHEMBL19667217 | 0.88 | PTGDR2 (0.46) | PTGDR2P2RX3ESR2 | |
| SCHEMBL19667403 | 0.88 | PTGDR2 (0.51) | PTGDR2 | |
| SCHEMBL20767978 | 0.86 | PTGDR2 (0.44) | PTGDR2P2RX3ESR2 | |
| SCHEMBL19667507 | 0.86 | PTGDR2 (0.44) | PTGDR2P2RX3 | |
| SCHEMBL19667110 | 0.85 | PTGDR2 (0.50) | PTGDR2P2RX3 | |
| SCHEMBL19667497 | 0.85 | PTGDR2 (0.48) | PTGDR2P2RX3 | |
| SCHEMBL19679357 | 0.83 | TLR9 (0.41) | PTGDR2 | |
| SCHEMBL23684726 | 0.82 | PTGDR2 (0.52) | PTGDR2ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10709709-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190111060-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2019-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10709709-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | DUT, NCL, TYMP | PTGDR2 4262/4885P2RX3 3952/4885ESR2 2951/4885 |
| US-20190111060-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | DUT, NCL, TYMP | PTGDR2 4262/4885P2RX3 3952/4885ESR2 2951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.